Peripheral blood lymphocytes predict clinical outcomes in hormone receptor-positive HER2-negative advanced breast cancer patients treated with CDK4/6 inhibitors.
Emma ZattarinLuigi MarianiAlice MenichettiRita LeporatiLeonardo ProvenzanoFrancesca LigorioGiovanni FucàRiccardo LobefaroLuca LalliAndrea VingianiFederico NichettiGaia GriguoloMarianna SiricoOttavia BernocchiAntonio MarraChiara CortiPaola ZagamiElisa AgostinettoFlavia JacobsPierluigi Di MauroDaniele PrestiCaterina SposettiCarlo Alberto GiorgiValentina GuarneriRebecca PedersiniAgnese LosurdoDaniele GeneraliGiuseppe CuriglianoGiancarlo PruneriFilippo de BraudMaria Vittoria DieciClaudio VernieriPublished in: Therapeutic advances in medical oncology (2023)
Baseline and on-treatment modifications of peripheral blood lymphocytes have independent prognostic value in HR+/HER2- aBC patients. This study supports the implementation of clinical strategies to boost antitumor immunity in patients with HR+/HER2- aBC treated with ETs plus CDK4/6i.